Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts

Archives of Physiology and Biochemistry

Volumn 113, Issue 3, 2007, Pages 154-161

  Franke, Sybille ^a   Siggelkow, Heide ^b   Wolf, Gunter ^a   Hein, Gert ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Advanced glycation endproducts; Bone; mRNA expression; Osteoblasts; RAGE; RANKL

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ALKALINE PHOSPHATASE; IMMUNOGLOBULIN RECEPTOR; MESSENGER RNA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PRIMER DNA; SP7 PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CELL CULTURE; CONFERENCE PAPER; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALKALINE PHOSPHATASE; BASE SEQUENCE; CELLS, CULTURED; DNA PRIMERS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOHISTOCHEMISTRY; OSTEOBLASTS; OSTEOCALCIN; RANK LIGAND; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS;

BOVINAE;

EID: 35148861052     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450701602523     Document Type: Conference Paper

References (33)

1. Bohlender JM, Franke S, Stein G, Wolf G. 2005. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 289:F645-59.
2. Cortizo AM, Lettieri MG, Barrio DA, Mercer N, Etcheverry SB, McCarthy AD. 2003. Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol Cell Biochem 250:1-10.
3. Franke S, Müller A, Sommer M, Busch M, Kientsch-Engel R, Stein G. 2003. Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. Clin Nephrol 59:88-97.
4. Harada S, Rodan GA. 2003. Control of osteoblast function and regulation of bone mass. Nature 423:349-55.
5. Hein G. 2006. Glycation endproducts in osteoporosis - is there a pathophysiologic importance? Clin Chim Arta 371:32-6.
6. Hein G, Weiss C, Lehmann G, Niwa T, Stein G, Franke S. 2006. Advanced glycation end product modification of bone proteins and bone remodelling: Hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis 65:101-4.
7. Hein G, Wiegand R, Lehmann G, Stein G, Franke S. 2003. Advanced glycation end-products pentosidine and N epsiloncarboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 42:1242-6.
8. Hofbauer LC, Heufelder AE. 2001. Role of receptor activator of nuclear factor-kB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243-53.
9. Kern A, Jundt G, Vonderheid B, Groscurth P, Schulz A. 1990. Establishment and functional characterization of a human osteosarcoma cell-line (HOS 58). Calcif Tissue Int (suppl 2) 46:A54.
10. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K, Takayanagi H. 2005. NFAT and Osterix cooperatively regulate bone formation. Nat Med 11:880-5.
11. Lin L. 2006. RAGE on the Toll Road? Cell Mol Immunol 3: 351-8.
12. McCarthy AD, Etcheverry SB, Bruzzone L, Cortizo AM. 1997. Effects of advanced glycation end-products on the proliferation and differentiation of osteoblast-like cells. Mol Cell Biochem 170:43-51.
13. McCarthy AD, Etcheverry SB, Cortizo AM. 2001. Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol 2:16.
14. Mercer N, Ahmed H, McCarthy AD, Etcheverry SB, Vasta GR, Cortizo AM. 2004. AGE-R3/galectin-3 expression in osteoblast-like cells: Regulation by AGEs. Mol Cell Biochem 266:17-24.
15. Nakashima K, de Crombrugghe B. 2003. Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends Genet 19:458-66.
16. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. 1992. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998-5004.
17. Odetti P, Rossi S, Monacelli F, Poggi A, Cirnigliaro M, Federici M, Federici A. 2005. Ann NY Acad Sci 1043:710-7.
18. Parfitt AM. 1979. Quantum concept of bone remodeling and turnover: implications for the pathogenesis of osteoporosis. Calcif Tissue Int 24:1 - 5.
19. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45.
20. Schmidt AM, Yan SD, Yan SF, Stern DM. 2001. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108:949-55.
21. Siggelkow H, Eidner T, Lehmann G, Viereck V, Raddatz D, Munzel U, Hein G, Huffner M. 2003. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. J Bone Miner Res 18:529-38.
22. Siggelkow H, Niedhart C, Kurre W, Ihbe A, Schulz A, Atkinson MJ, Hufner M. 1998. In vitro differentiation potential of a new human osteosarcoma cell line (HOS 58). Differentiation 63:81-91.
23. Siggelkow H, Schenck M, Rohde M, Viereck M, Tauber S, Atkinson MJ, Hufner M. 2003. Prolonged culture of HOS 58 human osteosarcoma cells with 1,25-(OH)2-D3, TGF-beta, and dexamethasone reveals physiological regulation of alkaline phosphatase, dissociated osteocalcin gene expression, and protein synthesis and lack of mineralization. J Cell Biochem 85:279-94.
24. Siggelkow H, Schulz H, Kaesler S, Benzler K, Atkinson MJ, Hufner M. 1999. 1,25 Dihydroxyvitamin-D3 attenuates the confluence-dependent differences in the osteoblast characteristic proteins alkaline phosphatase, procollagen I peptide, and osteocalcin. Calcif Tissue Int 64:414-21.
25. Singh R, Barden A, Mori T, Beilin L. 2001. Advanced glycation end-products: A review. Diabetologia 44:129-46.
26. Stein GS, Lian JB. 1993. Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 1993 14:424-42.
27. Teitelbaum SL. 2007. Osteoclasts: what do they do and how do they do it? Am J Pathol 170:427-35.
28. Thorpe SR, Baynes JW. 2003. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25:275-81.
29. Ulrich P, Cerami A. 2001. Protein glycation, diabetes, and aging. Recent Prog Horm Res 56:1-21.
30. Vlassara H, R Bucala, L Striker. 1994. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70:138-51.
31. Viereck V, Siggelkow H, Pannem R, Braulke T, Scharf JG, Kubler B. 2007. Alteration of the insulin-like growth factor axis during in vitro differentiation of the human osteosarcoma cell line HOS 58. J Cell Biochem 2007 [Epub ahead of print].
32. Yamamoto T. 2006. The role of AGEs for the pathogenesis of osteopenia in diabetes mellitus. Clin Calcium 16:1322-6.
33. Yamamoto T, Ozono K, Miyauchi A, Kasayama S, Kojima Y, Shima M, Okada S. 2001. Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 38:S161-4.